News for Mesoblast Limited (MSB.AX)

Every week, hundreds of companies go through the ups and downs of…

On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Shares of Interactive Brokers Group, Inc. IBKR rose sharply in pre-market trading after the company posted better-than-expected second-quarter results after Thu...

A strong all-round performance so the Australian share market posted a solid weekly gain as investors once again stayed bullish in the face of adversity.

The Mesoblast Ltd (ASX:MSB) share price is currently up 27% after the ASX biotech share reported its June 2025 quarterly update.

The local bourse has reached an all-time high after mining giant BHP lifted the stock market following record hauls for iron ore and copper. Near midday on Friday, the benchmark S&P/ASX200 index was up 59.4 points to 8,698.4, a gain of 0.69 per cent, while the broader All Ordinaries had gained 58 points, or 0.65 […]

Activity Report for Quarter Ended June 30, 2025 (Appendix 4C) NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (MESO; ASX:MSB), global leader i

Mesoblast (MESO) reports $13.2 million in revenue from Ryoncil® sales in its first quarter post-launch. Ryoncil® achieves coverage expansion to over 2

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Centene Corporation CNC fell sharply in today's p...

Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday. Shares of Mesoblast Limited MESO rose sharply during Tuesday's session aft...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity […]

**media[652385]**

Good Afternoon and welcome to HotCopper Highlights for Week 20, I’m Jon Davidson. In this segment we look at...

**media[626419]**

The ASX200 has been trading flat at around 8,280 points. Mesoblast (ASX:MSB)…